Correlation Between Kiromic Biopharma and Climb Bio
Can any of the company-specific risk be diversified away by investing in both Kiromic Biopharma and Climb Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kiromic Biopharma and Climb Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kiromic Biopharma and Climb Bio, you can compare the effects of market volatilities on Kiromic Biopharma and Climb Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kiromic Biopharma with a short position of Climb Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kiromic Biopharma and Climb Bio.
Diversification Opportunities for Kiromic Biopharma and Climb Bio
0.78 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Kiromic and Climb is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Kiromic Biopharma and Climb Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Climb Bio and Kiromic Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kiromic Biopharma are associated (or correlated) with Climb Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Climb Bio has no effect on the direction of Kiromic Biopharma i.e., Kiromic Biopharma and Climb Bio go up and down completely randomly.
Pair Corralation between Kiromic Biopharma and Climb Bio
If you would invest 268.00 in Kiromic Biopharma on October 1, 2024 and sell it today you would earn a total of 0.00 from holding Kiromic Biopharma or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 2.44% |
Values | Daily Returns |
Kiromic Biopharma vs. Climb Bio
Performance |
Timeline |
Kiromic Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Climb Bio |
Kiromic Biopharma and Climb Bio Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Kiromic Biopharma and Climb Bio
The main advantage of trading using opposite Kiromic Biopharma and Climb Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kiromic Biopharma position performs unexpectedly, Climb Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Climb Bio will offset losses from the drop in Climb Bio's long position.Kiromic Biopharma vs. Quoin Pharmaceuticals Ltd | Kiromic Biopharma vs. Allarity Therapeutics | Kiromic Biopharma vs. Virax Biolabs Group | Kiromic Biopharma vs. Biodexa Pharmaceticals |
Climb Bio vs. Eupraxia Pharmaceuticals Common | Climb Bio vs. Opus Genetics, | Climb Bio vs. Telix Pharmaceuticals Limited |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |